BBIO - BridgeBio reports additional positive data for acoramidis in ATTR-CM
2024-05-29 17:11:50 ET
More on BridgeBio Pharma
- BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident
- Cantor picks 14 undervalued biotech stocks worth a second look
- BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.31, revenue of $211.12M beats by $127.34M
- Seeking Alpha’s Quant Rating on BridgeBio Pharma
- Historical earnings data for BridgeBio Pharma